Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are conducting a multi-center clinical study to assess artificial intelligence AI algorithms for measuring heart function and size using echocardiography. The study aims to compare AI measurements with those of physicians at different experience levels, evaluate the accuracy and stability of AI, and explore its use in complex heart conditions like cardiomyopathy, valve disease, and coronary heart disease. The goal is to improve diagnostic consistency and clinical workflows across medical centers. The study involves measuring cardiac chamber size and function in 1600 participants using AI, senior physicians, and intermediate physicians. All measurements are made with Mindray ultrasonic machines. AI and intermediate physician results are completed within one day after data collection, while senior physician results are completed within one month. The study will establish a standardized reference system for AI-assisted echocardiographic measurements and evaluate AIs performance in special cases. Participants will undergo echocardiographic scans with measurements of left and right ventricular size and function, Doppler ultrasound indicators, and valve annulus displacements. Researchers will analyze data to compare AI and physician measurements, assess measurement deviations, and evaluate AIs efficiency in reducing analysis time. The study will run until July 2026, with ongoing data collection and analysis across multiple centers, aiming to promote wider clinical application of AI technology for cardiovascular disease diagnosis.
Actively Recruiting
Researchers are evaluating the efficacy and safety of recombinant botulinum toxin type A Eveotox in adults with upper limb spasticity following stroke. This phase III clinical trial compares Eveotox to a placebo to observe its effects on muscle spasticity and related functional improvements. Participants will receive Eveotox in a double-blind manner during the first treatment cycle, followed by up to three open-label cycles of Eveotox. Those initially assigned to placebo will receive placebo only during the first cycle and then transition to up to three cycles of Eveotox. The study aims to closely monitor the treatments impact over these cycles. During the trial, participants will undergo assessments to evaluate spasticity and functional abilities using scales such as the Modified Ashworth Scale and Disability Assessment Scale. Safety and efficacy will be tracked within four weeks for primary outcomes and up to 52 weeks for secondary measures. Participants will be monitored throughout the study duration, which lasts until January 2028, including safety checks and evaluations of treatment response.